<DOC>
	<DOCNO>NCT00165542</DOCNO>
	<brief_summary>The purpose study evaluate sensitivity specificity `` A-PROTEIN '' level patient brain tumor . A-PROTEIN level analyze pre post treatment . Levels blood and/or cerebrospinal fluid ( CSF ) analyze correlate underlying diagnosis outcome .</brief_summary>
	<brief_title>A-protein Levels Adult Pediatric Brain Tumor Patients</brief_title>
	<detailed_description>- Patients identified time presentation neurologist , neurosurgeon oncologist . - Blood cerebrospinal fluid collect study collect reason surgery . Samples also collect event significant change symptom radiographic progression . - Once patient condition stabilize , sample take regular interval &gt; = 1 month . The duration study 24 month .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<criteria>All patient possible malignant benign lesion central nervous system include . There restriction respect treatment protocol prior therapy . Patients identified presentation neurosurgical , neurological oncologic service participate center . Any patient evidence central nervous system tumor eligible . Individuals without evidence CNS tumor also eligible , order provide blind control . A sign informed consent request required participation . There age , sex , ethnic origin restriction protocol . Patients choose participate study continue regular care define treat team . Patients speak foreign language eligible long translator find ensure proper consent obtain . There exclusion criterion study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>77 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>A-protein level</keyword>
	<keyword>brain tumor</keyword>
</DOC>